Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Denali Therapeutics Inc.
Report date February 12, 2021 · Filed February 17, 2021
Jointly reported with BRATTON DOUGLAS K, Crestline SI (GP), L.P., Crestline Investors, Inc., Crestline Management, L.P.
Section 16 reporting ended · disclosed 2021-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy AKDL, L.P. | 9,984,836 |
Reported balance
After 2021-02-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-02-12 · Sale · Disposed 2,216,798 · Balance 9,984,836 F1: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. F2: (Continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Bratton Family Partners L.P. | 100,102 |
Reported balance
Holding disclosure · report date 2021-02-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 100,102 F3: These shares of common stock of the Issuer are held directly by Bratton Family Partners L.P., an entity controlled by Douglas K. Bratton. Such shares of common stock of the Issuer held by Bratton Family Partners L.P. were received in a previously reported pro rata in-kind distribution from Neuro Line Partners, L.P. without a change in pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.
F2: (Continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
F3: These shares of common stock of the Issuer are held directly by Bratton Family Partners L.P., an entity controlled by Douglas K. Bratton. Such shares of common stock of the Issuer held by Bratton Family Partners L.P. were received in a previously reported pro rata in-kind distribution from Neuro Line Partners, L.P. without a change in pecuniary interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 17, 2021 20:39 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,216,798 | $65.00 | $144,091,870.00 |
DisclosureSEC source: 0000899243-21-007016 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 9,984,836 F1 · ownership.nature: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. F2 · ownership.nature: (Continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 16:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,443,247 | $31.65 | $45,678,767.55 |
DisclosureSEC source: 0000899243-20-022430 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 12,201,634 F1 · ownership.nature: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. F2 · ownership.nature: (Continued from footnote 1) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 16:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,922,855 | $25.75 | $49,513,516.25 |
DisclosureSEC source: 0000899243-20-015779 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 13,644,881 F1 · ownership.nature: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. F2 · ownership.nature: (Continued in footnote 1) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 16:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,894,764 | $20.25 | $78,868,971.00 |
DisclosureSEC source: 0000899243-20-006252 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 15,567,736 F1 · ownership.nature: These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. F2 · ownership.nature: (continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · derivative · entry 13 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F3 · derivative.exercise_date: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F3 · derivative.expiration_date: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F6 · ownership.nature: These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F7 · ownership.nature: (Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 128,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · derivative · entry 12 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 128,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F2 · derivative.exercise_date: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F2 · derivative.expiration_date: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F6 · ownership.nature: These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F7 · ownership.nature: (Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 743,599 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · derivative · entry 11 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 743,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F1 · derivative.exercise_date: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F1 · derivative.expiration_date: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F6 · ownership.nature: These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F7 · ownership.nature: (Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 1,875,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · derivative · entry 10 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,875,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F3 · derivative.exercise_date: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F3 · derivative.expiration_date: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 2,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · derivative · entry 9 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F2 · derivative.exercise_date: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F2 · derivative.expiration_date: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 14,499,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · derivative · entry 8 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 0 Underlying: Common Stock · 14,499,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F1 · derivative.exercise_date: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F1 · derivative.expiration_date: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | PurchaseCommon Stock | 275,000 | $18.00 | $4,950,000.00 |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 7 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 19,462,499 F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 240,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 6 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 1,111,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F6 · ownership.nature: These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F7 · ownership.nature: (Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 128,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 5 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 871,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F6 · ownership.nature: These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F7 · ownership.nature: (Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 743,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 4 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 743,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F6 · ownership.nature: These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. F7 · ownership.nature: (Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 1,875,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 3 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 19,187,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 2 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 17,312,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 14,499,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-028694 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner AKDL, L.P. · CIK 0001716958 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AKDL, L.P. Disclosed balance after: 14,812,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date. F4 · ownership.nature: These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. F5 · ownership.nature: (Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.